WO2013028807A3 - Renal cell carcinoma biomarkers and uses thereof - Google Patents
Renal cell carcinoma biomarkers and uses thereof Download PDFInfo
- Publication number
- WO2013028807A3 WO2013028807A3 PCT/US2012/051944 US2012051944W WO2013028807A3 WO 2013028807 A3 WO2013028807 A3 WO 2013028807A3 US 2012051944 W US2012051944 W US 2012051944W WO 2013028807 A3 WO2013028807 A3 WO 2013028807A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell carcinoma
- renal cell
- biomarkers
- rcc
- carcinoma biomarkers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/30—Microarray design
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Evolutionary Biology (AREA)
- Organic Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Biomarkers for the detecion of Renal Cell Carcinoma (RCC) in an individual are provided. More specifically, one or more biomarkers, methods, devices, reagents, systems, and kits for the evaluation of RCC are provided, wherein the evaluation may comprise diagnosis, prognosis, determination of disease burden or determination of recurrence of RCC in an individual.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12824991.9A EP2748356A2 (en) | 2011-08-22 | 2012-08-22 | Renal cell carcinoma biomarkers and uses thereof |
MX2014002030A MX2014002030A (en) | 2011-08-22 | 2012-08-22 | Renal cell carcinoma biomarkers and uses thereof. |
CA2843756A CA2843756A1 (en) | 2011-08-22 | 2012-08-22 | Renal cell carcinoma biomarkers and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526133P | 2011-08-22 | 2011-08-22 | |
US61/526,133 | 2011-08-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013028807A2 WO2013028807A2 (en) | 2013-02-28 |
WO2013028807A3 true WO2013028807A3 (en) | 2014-05-15 |
Family
ID=47747076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/051944 WO2013028807A2 (en) | 2011-08-22 | 2012-08-22 | Renal cell carcinoma biomarkers and uses thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US20130065782A1 (en) |
EP (1) | EP2748356A2 (en) |
CA (1) | CA2843756A1 (en) |
MX (1) | MX2014002030A (en) |
WO (1) | WO2013028807A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ600268A (en) | 2010-01-11 | 2014-08-29 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
MX341517B (en) | 2010-08-13 | 2016-08-24 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof. |
EP3825420A1 (en) * | 2013-05-30 | 2021-05-26 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
US9322051B2 (en) | 2013-10-07 | 2016-04-26 | General Electric Company | Probing of biological samples |
US10908156B2 (en) | 2014-03-21 | 2021-02-02 | Nephrogen, Inc. | Portable instrument for in vitro detection and quantification of biomarkers |
AU2018402956A1 (en) * | 2018-01-16 | 2020-08-27 | Public University Corporation Yokohama City University | Renal cancer detection method and test drug |
JP7339337B2 (en) | 2018-11-07 | 2023-09-05 | トラスティーズ オブ タフツ カレッジ | Atomic force microscopy to identify surfaces |
CN110361242B (en) * | 2019-08-14 | 2022-01-18 | 武汉赛维尔生物科技有限公司 | Fixing liquid for eyeball tissue and pretreatment method for preparing eyeball tissue slices |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130193A1 (en) * | 2003-09-10 | 2005-06-16 | Luxon Bruce A. | Methods for detecting, diagnosing and treating human renal cell carcinoma |
WO2011050328A2 (en) * | 2009-10-22 | 2011-04-28 | The Regents Of The University Of California | Assessment of solid tumor burden |
US20110171633A1 (en) * | 2010-01-11 | 2011-07-14 | Wayne Cowens | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
-
2012
- 2012-08-22 MX MX2014002030A patent/MX2014002030A/en unknown
- 2012-08-22 CA CA2843756A patent/CA2843756A1/en not_active Abandoned
- 2012-08-22 US US13/592,267 patent/US20130065782A1/en not_active Abandoned
- 2012-08-22 EP EP12824991.9A patent/EP2748356A2/en not_active Withdrawn
- 2012-08-22 WO PCT/US2012/051944 patent/WO2013028807A2/en active Application Filing
-
2014
- 2014-12-10 US US14/566,431 patent/US20150160225A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130193A1 (en) * | 2003-09-10 | 2005-06-16 | Luxon Bruce A. | Methods for detecting, diagnosing and treating human renal cell carcinoma |
WO2011050328A2 (en) * | 2009-10-22 | 2011-04-28 | The Regents Of The University Of California | Assessment of solid tumor burden |
US20110171633A1 (en) * | 2010-01-11 | 2011-07-14 | Wayne Cowens | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
Also Published As
Publication number | Publication date |
---|---|
WO2013028807A2 (en) | 2013-02-28 |
US20150160225A1 (en) | 2015-06-11 |
CA2843756A1 (en) | 2013-02-28 |
MX2014002030A (en) | 2014-04-10 |
EP2748356A2 (en) | 2014-07-02 |
US20130065782A1 (en) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013028807A3 (en) | Renal cell carcinoma biomarkers and uses thereof | |
WO2012047618A3 (en) | Mesothelioma biomarkers and uses thereof | |
WO2009037572A3 (en) | Biomarker combinations for colorectal cancer | |
WO2012021795A3 (en) | Pancreatic cancer biomarkers and uses thereof | |
WO2014127290A3 (en) | Methods for predicting risk of interstitial pneumonia | |
WO2012038463A3 (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
WO2011106709A3 (en) | Epithelial biomarkers for cancer prognosis | |
WO2012006447A3 (en) | Gene signatures for cancer prognosis | |
WO2012012725A3 (en) | Methods of detecting diseases or conditions using phagocytic cells | |
WO2012021887A3 (en) | Biomarkers for the early detection of breast cancer | |
EP2611941A4 (en) | Gene signatures for cancer diagnosis and prognosis | |
MX340453B (en) | Biomarkers for lung cancer. | |
AR066725A1 (en) | PREDICTION OF THE FORECAST FOR MELANOMA DE CANCER | |
WO2012096545A3 (en) | Novel pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof | |
WO2013062515A3 (en) | Lung cancer biomarkers and uses thereof | |
WO2012170206A3 (en) | Color-producing diagnostic systems, reagents and methods | |
EP3176268A4 (en) | Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof | |
WO2011112845A3 (en) | Methods and compositions related to a multi-methylation assay to predict patient outcome | |
WO2010009171A3 (en) | Src activation for determining cancer prognosis and as a target for cancer therapy | |
WO2013124738A3 (en) | Methods and biomarkers for detection and prognosis of cervical cancer | |
WO2013044187A3 (en) | Detecting ovarian cancer | |
WO2012061904A8 (en) | Histone protein ubiquitination as a cancer biomarker | |
WO2014072832A3 (en) | Biomarkers for cervical cancer | |
WO2014160237A3 (en) | Methods of prognosing preeclampsia | |
WO2014052930A3 (en) | Biomarkers for prostate cancer prognosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12824991 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2843756 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002030 Country of ref document: MX |